MarketPulse

NBTXR3

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Nanobiotix

Nanobiotix's NBTXR3 Shows Striking 85.7% Response Rate in Lung Cancer Study

Nanobiotix reports promising Phase 2 data for NBTXR3 in inoperable lung cancer, showing 85.7% response rate versus <5% with standard treatment.
JNJNBTXPhase 2 clinical trialimmunotherapy
GlobeNewswire Inc.GlobeNewswire Inc.··Nanobiotix

Nanobiotix's Lung Cancer Drug Shows Striking 85.7% Response Rate in Phase 2 Trial

Nanobiotix reports promising Phase 2 data for JNJ-1900 (NBTXR3) in inoperable lung cancer, achieving 85.7% overall response rate versus standard care's <5% complete response rate.
JNJNBTXPhase 2 clinical trialimmunotherapy
BenzingaBenzinga··Vandana Singh

Nanobiotix Shoots Down J&J Acquisition Rumors, Stock Soars on Clarity

Nanobiotix denies J&J acquisition rumors, shares rise 6.17%. Stock up 774.83% annually; reaffirms focus on advancing cancer pipeline, NBTXR3 partnership.
JNJNBTXcancer treatmentbiotechnology